BCPC vs UFPI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Balchem Corporation exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust fundamentals and operational efficiency. Despite this, the stock trades at a premium valuation (P/E 36.74 vs sector avg 29.27) above both the Graham Number ($64.13) and intrinsic value estimate ($134.52), raising concerns about overvaluation. While earnings and revenue growth are solid (20.4% YoY EPS, 11.5% revenue), insider selling activity and a bearish technical trend signal caution. The company's low debt (D/E 0.13) and consistent earnings beat history support stability, but stretched valuations limit near-term upside potential.
UFPI presents a stark dichotomy between a pristine balance sheet and deteriorating operational performance. With a Piotroski F-Score of 4/9, the company is fundamentally stable but lacks growth momentum, evidenced by a -39.7% YoY earnings decline and four consecutive quarterly misses. The stock trades at $96.20, significantly above its Graham Number ($78.02) and far above its Intrinsic Value ($35.00), suggesting a valuation premium that is not supported by current fundamentals. While exceptionally low debt provides a safety net, the bearish technical trend and negative growth trajectory outweigh the optimistic analyst consensus.
Compare Another Pair
Related Comparisons
BCPC vs UFPI: Head-to-Head Comparison
This page compares Balchem Corporation (BCPC) and UFP Industries, Inc. (UFPI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.